Epic Sciences, founded to advance medical diagnostics, specializes in characterizing circulating tumor cells (CTCs). The company's core mission is to provide comprehensive cancer profiling through innovative technologies. Their flagship service involves a multi-technology approach using a single blood draw to analyze CTCs, circulating tumor DNA (ctDNA), and immune cells. This service offers critical insights for clinicians and drug developers, particularly in the fields of prostate and breast cancer.
Notable figures affiliated with Epic Sciences include its founders and key investors from the biotech and medical sectors. The company has achieved significant milestones, including the development of proprietary CTC capabilities and successful partnerships with leading biopharma companies. Epic Sciences' impact is evident in its contributions to precision medicine, offering enhanced diagnostic clarity and aiding in the development of targeted cancer therapies.
